Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Reply to Million and Raoult.

de Lange MMA, Gijsen LEV, Wielders CCH, van der Hoek W, Scheepmaker A, Schneeberger PM.

Clin Infect Dis. 2019 Jan 1;68(1):170-171. doi: 10.1093/cid/ciy536. No abstract available.

PMID:
29985990
2.

Correction: Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands.

Teunis PFM, Evers EG, Hengeveld PD, Dierikx CM, Wielders CCH, van Duijkeren E.

PLoS One. 2018 Apr 23;13(4):e0196492. doi: 10.1371/journal.pone.0196492. eCollection 2018.

3.

Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands.

Teunis PFM, Evers EG, Hengeveld PD, Dierikx CM, Wielders CCH, van Duijkeren E.

PLoS One. 2018 Mar 21;13(3):e0193834. doi: 10.1371/journal.pone.0193834. eCollection 2018. Erratum in: PLoS One. 2018 Apr 23;13(4):e0196492.

4.

Should Acute Q-Fever Patients be Screened for Valvulopathy to Prevent Endocarditis?

de Lange MMA, Gijsen LEV, Wielders CCH, van der Hoek W, Scheepmaker A, Schneeberger PM.

Clin Infect Dis. 2018 Jul 18;67(3):360-366. doi: 10.1093/cid/ciy128.

5.

Long-term Carriage of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in the General Population in The Netherlands.

van Duijkeren E, Wielders CCH, Dierikx CM, van Hoek AHAM, Hengeveld P, Veenman C, Florijn A, Lotterman A, Smit LAM, van Dissel JT, Maassen CBM, de Greeff SC.

Clin Infect Dis. 2018 Apr 17;66(9):1368-1376. doi: 10.1093/cid/cix1015.

PMID:
29149242
6.

Prevalence and risk factors for colonization of Clostridium difficile among adults living near livestock farms in the Netherlands.

Zomer TP, VAN Duijkeren E, Wielders CCH, Veenman C, Hengeveld P, VAN DER Hoek W, DE Greeff SC, Smit LAM, Heederik DJ, Yzermans CJ, Kuijper EJ, Maassen CBM.

Epidemiol Infect. 2017 Oct;145(13):2745-2749. doi: 10.1017/S0950268817001753. Epub 2017 Aug 14.

PMID:
28805171
7.

MRSA in persons not living or working on a farm in a livestock-dense area: prevalence and risk factors.

Zomer TP, Wielders CC, Veenman C, Hengeveld P, van der Hoek W, de Greeff SC, Smit LA, Heederik DJ, Yzermans CJ, Bosch T, Maassen CB, van Duijkeren E.

J Antimicrob Chemother. 2017 Mar 1;72(3):893-899. doi: 10.1093/jac/dkw483.

PMID:
27999031
8.

Extended-spectrum β-lactamase- and pAmpC-producing Enterobacteriaceae among the general population in a livestock-dense area.

Wielders CCH, van Hoek AHAM, Hengeveld PD, Veenman C, Dierikx CM, Zomer TP, Smit LAM, van der Hoek W, Heederik DJ, de Greeff SC, Maassen CBM, van Duijkeren E.

Clin Microbiol Infect. 2017 Feb;23(2):120.e1-120.e8. doi: 10.1016/j.cmi.2016.10.013. Epub 2016 Oct 20.

9.

Use of a Dose-Response Model to Study Temporal Trends in Spatial Exposure to Coxiella burnetii: Analysis of a Multiyear Outbreak of Q Fever.

Brooke RJ, Teunis PF, Kretzschmar ME, Wielders CC, Schneeberger PM, Waller LA.

Zoonoses Public Health. 2017 Mar;64(2):118-126. doi: 10.1111/zph.12288. Epub 2016 Aug 23.

PMID:
27549241
10.

Kinetics of antibody response to Coxiella burnetii infection (Q fever): Estimation of the seroresponse onset from antibody levels.

Wielders CC, Teunis PF, Hermans MH, van der Hoek W, Schneeberger PM.

Epidemics. 2015 Dec;13:37-43. doi: 10.1016/j.epidem.2015.07.001. Epub 2015 Jul 26.

11.

Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic.

Wielders CC, van Loenhout JA, Morroy G, Rietveld A, Notermans DW, Wever PC, Renders NH, Leenders AC, van der Hoek W, Schneeberger PM.

PLoS One. 2015 Jul 10;10(7):e0131848. doi: 10.1371/journal.pone.0131848. eCollection 2015.

12.

Persistent high IgG phase I antibody levels against Coxiella burnetii among veterinarians compared to patients previously diagnosed with acute Q fever after three years of follow-up.

Wielders CC, Boerman AW, Schimmer B, van den Brom R, Notermans DW, van der Hoek W, Schneeberger PM.

PLoS One. 2015 Jan 20;10(1):e0116937. doi: 10.1371/journal.pone.0116937. eCollection 2015.

13.

Severely impaired health status of non-notified Q fever patients leads to an underestimation of the true burden of disease.

van Loenhout JA, Wielders CC, Morroy G, Cox MJ, van der Hoek W, Hautvast JL, Paget WJ, van der Velden J.

Epidemiol Infect. 2015 Sep;143(12):2580-7. doi: 10.1017/S0950268814003689. Epub 2015 Jan 13.

PMID:
25582890
14.

Single nucleotide polymorphisms in immune response genes in acute Q fever cases with differences in self-reported symptoms.

Wielders CC, Hackert VH, Schimmer B, Hodemaekers HM, de Klerk A, Hoebe CJ, Schneeberger PM, van Duynhoven YT, Janssen R.

Eur J Clin Microbiol Infect Dis. 2015 May;34(5):943-50. doi: 10.1007/s10096-014-2310-9. Epub 2015 Jan 11.

PMID:
25577174
15.

Persistent high antibody titres against Coxiella burnetii after acute Q fever not explained by continued exposure to the source of infection: a case-control study.

Jajou R, Wielders CC, Leclercq M, van Leuken J, Shamelian S, Renders N, van der Hoek W, Schneeberger P.

BMC Infect Dis. 2014 Nov 25;14:629. doi: 10.1186/s12879-014-0629-6.

16.

Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands.

Wielders CC, Wuister AM, de Visser VL, de Jager-Leclercq MG, Groot CA, Dijkstra F, van Gageldonk-Lafeber AB, van Leuken JP, Wever PC, van der Hoek W, Schneeberger PM.

PLoS One. 2014 Mar 10;9(3):e91764. doi: 10.1371/journal.pone.0091764. eCollection 2014.

17.

Correlations between peripheral blood Coxiella burnetii DNA load, interleukin-6 levels, and C-reactive protein levels in patients with acute Q fever.

Kremers MN, Janssen R, Wielders CC, Kampschreur LM, Schneeberger PM, Netten PM, de Klerk A, Hodemaekers HM, Hermans MH, Notermans DW, Wever PC.

Clin Vaccine Immunol. 2014 Apr;21(4):484-7. doi: 10.1128/CVI.00715-13. Epub 2014 Jan 29.

18.

Spatial analysis of positive and negative Q fever laboratory results for identifying high- and low-risk areas of infection in the Netherlands.

van den Berg EJ, Wielders CC, Schneeberger PM, Wegdam-Blans MC, van der Hoek W.

Infect Ecol Epidemiol. 2013 Nov 28;3. doi: 10.3402/iee.v3i0.20432. eCollection 2013.

19.

High Coxiella burnetii DNA load in serum during acute Q fever is associated with progression to a serologic profile indicative of chronic Q fever.

Wielders CC, Wijnbergen PC, Renders NH, Schellekens JJ, Schneeberger PM, Wever PC, Hermans MH.

J Clin Microbiol. 2013 Oct;51(10):3192-8. doi: 10.1128/JCM.00993-13. Epub 2013 Jul 17.

20.

Large regional differences in serological follow-up of Q fever patients in the Netherlands.

Morroy G, Wielders CC, Kruisbergen MJ, van der Hoek W, Marcelis JH, Wegdam-Blans MC, Wijkmans CJ, Schneeberger PM.

PLoS One. 2013;8(4):e60707. doi: 10.1371/journal.pone.0060707. Epub 2013 Apr 5.

21.

Strategies for early detection of chronic Q-fever: a systematic review.

Wielders CC, Morroy G, Wever PC, Coutinho RA, Schneeberger PM, van der Hoek W.

Eur J Clin Invest. 2013 Jun;43(6):616-39. doi: 10.1111/eci.12073. Epub 2013 Mar 29. Review.

PMID:
23550525
22.

Early diagnosis and treatment of patients with symptomatic acute Q fever do not prohibit IgG antibody responses to Coxiella burnetii.

Wielders CC, Kampschreur LM, Schneeberger PM, Jager MM, Hoepelman AI, Leenders AC, Hermans MH, Wever PC.

Clin Vaccine Immunol. 2012 Oct;19(10):1661-6. Epub 2012 Aug 22.

23.

Detection of phase I IgG antibodies to Coxiella burnetii with EIA as a screening test for blood donations.

van der Hoek W, Wielders CC, Schimmer B, Wegdam-Blans MC, Meekelenkamp J, Zaaijer HL, Schneeberger PM.

Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3207-9. doi: 10.1007/s10096-012-1686-7. Epub 2012 Jul 10.

PMID:
22777593
24.

Screening for Coxiella burnetii seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the Dutch Q fever outbreak.

Kampschreur LM, Hagenaars JC, Wielders CC, Elsman P, Lestrade PJ, Koning OH, Oosterheert JJ, Renders NH, Wever PC.

Epidemiol Infect. 2013 Apr;141(4):847-51. doi: 10.1017/S0950268812001203. Epub 2012 Jun 13.

PMID:
22691867
25.

Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention.

Steens A, Wielders CC, Bogaards JA, Boshuizen HC, de Greeff SC, de Melker HE.

Int J Cancer. 2013 Feb 15;132(4):932-43. doi: 10.1002/ijc.27671. Epub 2012 Jul 3.

26.

Evaluation of commonly used serological tests for detection of Coxiella burnetii antibodies in well-defined acute and follow-up sera.

Wegdam-Blans MC, Wielders CC, Meekelenkamp J, Korbeeck JM, Herremans T, Tjhie HT, Bijlmer HA, Koopmans MP, Schneeberger PM.

Clin Vaccine Immunol. 2012 Jul;19(7):1110-5. doi: 10.1128/CVI.05581-11. Epub 2012 May 23.

27.

Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children.

Wijngaard CC, Asten Lv, Koopmans MP, Pelt Wv, Nagelkerke NJ, Wielders CC, Lier Av, Hoek Wv, Meijer A, Donker GA, Dijkstra F, Harmsen C, Sande MA, Kretzschmar M.

PLoS One. 2012;7(2):e31197. doi: 10.1371/journal.pone.0031197. Epub 2012 Feb 3.

28.

Mumps epidemic in orthodox religious low-vaccination communities in the Netherlands and Canada, 2007 to 2009.

Wielders CC, van Binnendijk RS, Snijders BE, Tipples GA, Cremer J, Fanoy E, Dolman S, Ruijs Wl, Boot HJ, de Melker HE, Hahne SJ.

Euro Surveill. 2011 Oct 13;16(41). pii: 19989.

29.

Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis.

Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW; WHO Working Group for Risk Factors for Severe H1N1pdm Infection.

PLoS Med. 2011 Jul;8(7):e1001053. doi: 10.1371/journal.pmed.1001053. Epub 2011 Jul 5.

30.

Nowcasting pandemic influenza A/H1N1 2009 hospitalizations in the Netherlands.

Donker T, van Boven M, van Ballegooijen WM, Van't Klooster TM, Wielders CC, Wallinga J.

Eur J Epidemiol. 2011 Mar;26(3):195-201. doi: 10.1007/s10654-011-9566-5. Epub 2011 Mar 18.

31.

The burden of 2009 pandemic influenza A(H1N1) in the Netherlands.

Wielders CC, van Lier EA, van 't Klooster TM, van Gageldonk-Lafeber AB, van den Wijngaard CC, Haagsma JA, Donker GA, Meijer A, van der Hoek W, Lugnér AK, Kretzschmar ME, van der Sande MA.

Eur J Public Health. 2012 Feb;22(1):150-7. doi: 10.1093/eurpub/ckq187. Epub 2010 Dec 22.

PMID:
21183472
32.

Surveillance of hospitalisations for 2009 pandemic influenza A(H1N1) in the Netherlands, 5 June - 31 December 2009.

van 't Klooster TM, Wielders CC, Donker T, Isken L, Meijer A, van den Wijngaard CC, van der Sande MA, van der Hoek W.

Euro Surveill. 2010 Jan 14;15(2). pii: 19461.

Supplemental Content

Loading ...
Support Center